Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment

Kamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDA On approval by FDA, the product will represent a new option in a market where supply... Biopharmaceuticals, FDA Kamada, Kedrion, rabies, KamRAB
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Rabies